Sign inJoin waitlistJoin the waitlist

Paul Viscuse

Assistant Professor, Medicine: Hematology and Oncology · University of Virginia Medical Center

Credentials: · · · · · · ·

History

University of Virginia Medical Center
Present
University of Virginia Medical Center
Present

Hematology and Medical Oncology
University of Texas Health Science Center at Houston
2019–2022
Internal Medicine
Mayo Clinic College of Medicine and Science
2016–2019
Tufts University in Boston, Massachusetts
Marshall University - Joan C. Edwards School of Medicine
2012–2016
Stonehill College in Easton, Massachusetts, followed
2008–2012

Research

Clinical considerations for the management of androgen indifferent prostate cancer
Review · Prostate Cancer and Prostatic Diseases · 2021 · Co-first of 4 authors · 51 citations
First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma-A Retrospective Study
Frontiers in Oncology · 2019 · First of 5 authors · 46 citations
Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal…
Case report · Frontiers in Oncology · 2021 · First of 11 authors · 44 citations

Ana Aparicio
6 papers
Robert Dreicer
5 papers
Andrew Hahn
4 papers · 2 as a fellow
Christopher Logothetis
4 papers
Jack Masur
4 papers · 4 as a fellow
Kathryn Ruddy
4 papers
Patrick Pilié
4 papers
Amishi Shah
3 papers
DG
Daniel Grass
3 papers
Eric Singer
3 papers
Jianjun Gao
3 papers
Katharine Price
3 papers

Clinical trials

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
Principal investigator · Recruiting · Phase 1, Phase 2
University of Virginia
2026–2032
Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)
Principal investigator · Recruiting
Paul Viscuse
2024–2027
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Site PI · Recruiting · Phase 3
Canadian Cancer Trials Group
2025–2031
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032